NCT02347449View on ClinicalTrials.gov

The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions
OTHER

Questionnaires, Oncotype Dx Assay

"1. Physician pre-assay questionnaire~2. Patient pre-assay questionnaire~3. Oncotype DX® Assay~4. Physician post- assay questionnaire~5. Patient post-assay questionnaire"

Trial Locations (1)

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

Sponsors

Collaborators (1)

Genomic Health®, Inc.
All Listed Sponsors
collaborator

Genomic Health®, Inc.

INDUSTRY

lead

Sunnybrook Health Sciences Centre

OTHER

NCT02347449 - The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population | Biotech Hunter | Biotech Hunter